Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Kyntra Bio (KYNB) Stock Price & Analysis

KYNB Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 15.24M
Enterprise Value
-CHF 38.76M
Total Cash (Recent Filing)
CHF 91.32M
Total Debt (Recent Filing)
CHF 0
Price to Earnings (P/E)
0.1
Beta
N/A
Next Earnings
Nov 09, 2026 (Est.)
EPS Estimate
-2.93
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Cash Runway

The stated cash runway into 2028 gives Kyntra time to advance its clinical programs without an immediately pressing financing event. This supports milestone execution and preserves strategic flexibility, although continued spending means the runway depends on disciplined cash management.

Clinical Pipeline Progress

A defined Phase II study with active enrollment, multiple dose levels, and a near-term interim analysis creates a measurable path toward clinical validation. Progress in this program could strengthen partnering prospects and establish a clearer development trajectory for the oncology pipeline.

Liability Reduction

Lower future payment obligations improve the company’s financial flexibility and reduce the burden placed on future royalty streams. The revised financing structure also allows Kyntra to retain subsequent royalties after the capped obligation is satisfied, supporting longer-term cash generation potential.

Bears Say

Revenue Contraction

Sustained revenue contraction weakens the operating base supporting Kyntra’s research platform and increases reliance on financing, royalties, or successful product development. The sharp gross-margin deterioration and continuing operating losses also make reported earnings less representative of durable business performance.

Cash Burn And Negative Equity

Ongoing cash consumption and a negative equity position limit financial resilience even after debt fell to zero. Continued investment in clinical programs may require substantial funding, while weak cash conversion reduces the company’s ability to support operations internally over the medium term.

Nasdaq Listing Uncertainty

The pending delisting appeal creates a structural corporate and financing risk rather than a temporary market fluctuation. Losing the Nasdaq listing could reduce market access, complicate future capital raising, and weaken institutional participation while compliance remains unresolved.

Kyntra Bio News

KYNB FAQ

What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is CHF15.24M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s next earnings report is estimated for Nov 09, 2026 (not yet confirmed), which is in 7 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported CHF2.441 earnings per share for the quarter, beating the consensus estimate of -CHF2.626 by CHF5.068.
Is Kyntra Bio overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -2.93.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of CHF2.441 in its last earnings report, beating expectations of -CHF2.626. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Kyntra Bio?
Hedge funds hold Kyntra Bio shares: the largest hedge-fund position in Kyntra Bio is 1,190,925,798 shares, and hedge funds decreased their holdings by 58.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology